Clinical Study
Low Serum Levels of Myeloid Progenitor Inhibitory Factor-1 Predict Good Response to Methotrexate in Rheumatoid Arthritis
Table 1
Baseline characteristics of the 3 categories of change in DAS28-3v.
| | Baseline characteristics ((mean ± SD), unless specified) | Change in DAS28-3v (0–12 weeks) | | ≥1.2 () | 0.6 to 1.2 () | <0.6 () |
| | MPIF-1 (pg/mL) | 1171.0 ± 670.8* | 1570.0 ± 728.3 | 1816.7 ± 1154.1 | | MCP-2 (pg/mL) | 29.5 ± 18.3 | 29.2 ± 22.2 | 36.7 ± 27.2 | | DAS28-3v |
5.9 ± 0.9 | 6.3 ± 0.8 | 6.1 ± 0.7 | | ESR (mm first hour) | 57.2 ± 31.2 | 77 ± 34.9 | 60.5 ± 31.3 | | Duration of disease (years) | 3.8 ± 3.9 | 4.1 ± 3 | 6 ± 5.1 | | Age (years) | 43.7 ± 10.4 | 42.3 ± 8.2 | 42.4 ± 12.8 | | RF positive (%) | 8 (89) | 6 (60) | 16 (59) | | Female gender (%) | 5 (56) | 9 (90) | 21 (78) |
|
|
compared to DAS28-3v < 0.6.
|
